Arena Pharma (ARNA) Volatility Up; Shares Trade Higher into VIVUS (VVUS) PDUFA for Qnexa
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) volatility is elevated as shares continue to trickle higher Thursday.
Market data shows implied volatility up 15 percent from Tuesday's close and at 67 percent of its annual trailing daily average. Implied volatility is currently at 97 percent.
Shares are about 6.9 percent better with decent volume in the post-holiday session.
Arena has been tepid following FDA approval of its weight-loss drug lorcaserin in late June. Many could be trading on peer VIVUS (Nasdaq: VVUS), which has a PDUFA date of July 17th for its Qnexa obesity pill.
Market data shows implied volatility up 15 percent from Tuesday's close and at 67 percent of its annual trailing daily average. Implied volatility is currently at 97 percent.
Shares are about 6.9 percent better with decent volume in the post-holiday session.
Arena has been tepid following FDA approval of its weight-loss drug lorcaserin in late June. Many could be trading on peer VIVUS (Nasdaq: VVUS), which has a PDUFA date of July 17th for its Qnexa obesity pill.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
- Dell Technologies (DELL) call put ratio 1 call to 1 put with a focus on expiring August options
- NVIDIA (NVDA) 10K contracts of September 125 puts trade
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
